Retrophin closes sale of Priority Review Voucher

7 July 2015

US drugmaker Retrophin (Nasdaq: RTRX) says it has closed the agreement to sell its Rare Pediatric Disease Priority Review Voucher to French pharma major Sanofi (Euronext: SAN).

Under the terms of the agreement, Retrophin has received a payment of $150 million, and will receive two additional trances of $47.5 million in 2016 and 2017.

Retrophin received the Pediatric PRV when Cholbam (cholic acid) was approved by the US Food and Drug Administration for the treatment of pediatric and adult patients suffering from bile acid synthesis disorders and entered an agreement with Sanofi in May (The Pharma Letter May 28). Last July, Sanofi and partner Regeneron Pharmaceuticals (Nasdaq: REGN) agreed to buy BioMarin Pharmaceuticals’ pediatric voucher for $67.5 million, aiming to help them accelerate their experimental cholesterol drug, the PCSK9 inhibitor Praluent (alirocumab), through the regulatory review process.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK